SCHEMBL30009505

SCHEMBL30009505

O=C1CCN(Cc2ccc(-c3ccnc4[nH]ccc34)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 9/20 0.52
CHUK O15111 8/20 0.52
NEK1 Q96PY6 4/20 0.50
ROCK1 Q13464 3/20 0.50
AURKB Q96GD4 2/20 0.50
DAPK3 O43293 1/20 0.50
JAK2 O60674 1/20 0.50
PRKD3 O94806 1/20 0.50
MAP4K4 O95819 1/20 0.50
PAK4 O96013 1/20 0.50
CSF1R P07333 1/20 0.50
RET P07949 1/20 0.50
IGF1R P08069 1/20 0.50
FGFR1 P11362 1/20 0.50
PRKACA P17612 1/20 0.50
FLT1 P17948 1/20 0.50
LTK P29376 1/20 0.50
GRK5 P34947 1/20 0.50
KDR P35968 1/20 0.50
MAP2K2 P36507 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4790060 0.88 NEK1 (0.59) IKBKBCHUKNEK1ROCK1AURKB
SCHEMBL31735093 0.88 NEK1 (0.59) IKBKBCHUKNEK1ROCK1AURKB
SCHEMBL4792388 0.86 NEK1 (0.61) IKBKBCHUKNEK1ROCK1AURKB
SCHEMBL4790023 0.86 NEK1 (0.61) IKBKBCHUKNEK1ROCK1AURKB
SCHEMBL14462835 0.86 NEK1 (0.61) IKBKBCHUKNEK1ROCK1AURKB
SCHEMBL18852731 0.85 ROCK2 (0.55) IKBKBCHUKNEK1ROCK1AURKB
SCHEMBL19823107 0.85 JAK1 (0.56) IKBKBCHUKNEK1ROCK1AURKB
SCHEMBL4792087 0.84 NEK1 (0.62) IKBKBCHUKNEK1ROCK1AURKB
SCHEMBL4790876 0.84 MAP3K11 (0.56) IKBKBCHUKNEK1ROCK1AURKB
SCHEMBL4763322 0.83 NEK1 (0.53) IKBKBCHUKNEK1ROCK1AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 IKBKB 294/4885CHUK 53/4885NEK1 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.